Affiliations 

  • 1 New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA. Electronic address: mlewiecki@gmail.com
  • 2 Osteoporosis Clinical Center and Research Program, University of Wisconsin, Madison, WI, USA
  • 3 Division of Clinical Immunology and Rheumatology, Department of Medicine, UAB Osteoporosis Prevention and Treatment Clinic, University of Alabama at Birmingham, Birmingham, AL, USA
  • 4 Swedish Medical Group, Seattle, WA, USA
  • 5 Rede Mater Dei de Saúde - Densimater, Belo Horizonte, Brazil
  • 6 Galway University Hospitals, National University of Ireland, Galway, Ireland
  • 7 Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA
  • 8 Illinois Bone and Joint Institute, LLC., Morton Grove, IL, USA
  • 9 JK Lee Orthopaedics & Traumatology, Petaling Jaya, Malaysia
  • 10 University of Manitoba, Winnipeg, Manitoba, Canada
J Clin Densitom, 2016 Apr-Jun;19(2):127-40.
PMID: 27020004 DOI: 10.1016/j.jocd.2016.03.003

Abstract

Dual-energy X-ray absorptiometry (DXA) is a technology that is widely used to diagnose osteoporosis, assess fracture risk, and monitor changes in bone mineral density (BMD). The clinical utility of DXA is highly dependent on the quality of the scan acquisition, analysis, and interpretation. Clinicians are best equipped to manage patients when BMD measurements are correct and interpretation follows well-established standards. Poor-quality acquisition, analysis, or interpretation of DXA data may mislead referring clinicians, resulting in unnecessary diagnostic evaluations, failure to evaluate when needed, inappropriate treatment, or failure to provide medical treatment, with potentially ineffective, harmful, or costly consequences. Misallocation of limited healthcare resources and poor treatment decisions can be minimized, and patient care optimized, through meticulous attention to DXA instrument calibration, data acquisition and analysis, interpretation, and reporting. This document from the International Society for Clinical Densitometry describes quality standards for BMD testing at DXA facilities worldwide to provide guidance for DXA supervisors, technologists, interpreters, and clinicians. High-quality DXA testing is necessary for correct diagnostic classification and optimal fracture risk assessment, and is essential for BMD monitoring.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.